Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease.

Related Articles Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Aug;23(8):1316-1327 Authors: Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI Abstract BACKGROUND: It is unclear whether the combination of adalimumab (ADA) and immunomodulators is superior to ADA monotherapy in patients with Crohn’s disease. METHODS: PubMed, Medline, Embase, Web of Science, and other databases were searched. Randomized controlled trials, open-label, prospective cohort, and retrospective studies, and pooled analyses were included. Primary…

Read More

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflamm Bowel Dis. 2017 Jul 12;: Authors: Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P Abstract BACKGROUND: Little is known about the association between the pharmacokinetic features of adalimumab (ADL) and disease outcome in patients with inflammatory bowel disease (IBD). AIMS: To assess the association between random serum ADL levels and clinical or biochemical remission with clinical decision…

Read More

Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors.

Related Articles Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 May 08;: Authors: Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM Abstract BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn’s disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn’s disease according to different disease endpoints,…

Read More

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Related Articles Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Apr 12;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M PMID: 28405767 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28405767?dopt=Abstract

Read More

Adalimumab Vs Azathioprine in the Prevention of Postoperative Crohn’s Disease Recurrence. A Geteccu Randomized Trial.

Adalimumab Vs Azathioprine in the Prevention of Postoperative Crohn’s Disease Recurrence. A Geteccu Randomized Trial. J Crohns Colitis. 2017 Apr 11;: Authors: López-Sanromán A, Vera-Mendoza I, Domènech E, Taxonera C, Vega Ruiz V, Marín-Jiménez I, Guardiola J, Castro L, Esteve M, Iglesias E, Ceballos D, Martínez-Montiel P, Gisbert JP, Mínguez M, Echarri A, Calvet X, Barrio J, Hinojosa J, Martín-Arranz MD, Márquez-Mosquera L, Bermejo F, Rimola J, Pons V, Nos P, Spanish GETECCU group (APPRECIA study) Abstract Background and Aims: Postoperative recurrence of Crohn’s disease (POR-CD) is almost certain if…

Read More

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 Mar 16;: Authors: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L Abstract BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn’s disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to…

Read More

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Related Articles Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Mar 20;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M Abstract BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and response…

Read More

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Mar 20;: Authors: Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R Abstract BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary…

Read More
<< Go Back